

EXECUTIVE SUMMARY

Full Year 2021




Main figures €m

REVENUE 648.7 (+54%)	EBITDA 202.9 (+115%)	EBIT 181.6 (+143%)
Net profit 153.1 (+151%)	Capex 40.9 (+3%)	Net cash 27.4


2022 operating revenue guidance upgraded to +15%-20%

ROVI receives the European Commission's approval of Okedi® as a treatment for schizophrenia

Operating revenue €m



Specialty pharma business €m



Heparin franchise* €242.0 (+16%) 37% of operating revenue

LMWH €234.8 (+16%)

Bemiparin sales

€110.7m (+9%)

Spain €69.4m (+1%)

International €41.3m (+25%)

Enoxaparin sales

€124.0m (+22%)

✓ Directly marketed in Germany, UK, Italy, Portugal, Spain and Poland

✓ Approved in 26 countries in Europe and 27 in RoW


✓ Launched in 32 countries.

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins


CMO business €m

Total €264.7m (+189%)

Gross margin €m



SG&A expenses €m




R&D expenses €m €27.4 +15%

Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Phase III	<ul style="list-style-type: none"> Approved in Europe In approval process in USA
Letrozole ISM® Long acting Letrozole	Breast Cancer	Phase I	Phase I started in November 2017
Risperidone, quarterly	Schizophrenia	Non-Clinical	


Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

EBITDA €m



NET PROFIT €m



News flow

SPECIALTY PHARMA

- Sales of enoxaparin biosimilar
- Additional new products to be launched
- Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

CMO

- New contracts to be announced
- Evolution of Moderna's vaccine manufacturing.

ISM® Technology platform

- Launch of Okedi® in Europe
- Marketing authorization for Risvan® in USA
- Discussions with FDA initiated to review Letrozole ISM® phase I results as well as next steps

1. Calculated excluding R&D expenses in 2021 and 2020